Key Highlights

  • Zoetis lowered 2026 revenue guidance to $9.12 billion to $9.32 billion and adjusted EPS guidance to $6.15 to $6.25.
  • Second-quarter revenue was about $2.5 billion, flat reported, while adjusted net income was $781 million, or $1.87 per share.
  • US companion-animal revenue fell 11% in the quarter, while US livestock revenue rose 23% and international revenue grew 8%.
  • An annualized dividend of about $2.12 per share equals roughly 34% of the midpoint of adjusted earnings guidance.

The dividend at Zoetis Inc. (NYSE:ZTS) looks comfortably covered by earnings as of September 30, 2026, even after the company cut its full-year outlook, though the reduced guidance narrows the room for faster increases. The animal-health group declared a quarterly payment of $0.53 per share in February 2026, and the revised adjusted earnings range implies that an annualized payout of about $2.12 would absorb roughly a third of profit. That is an analytical estimate rather than company disclosure, and it rests on guidance that has already been lowered.

A pure-play animal-health business

Zoetis develops and sells medicines, vaccines and diagnostics for pets and livestock. The shares are listed on the New York Stock Exchange under the ticker ZTS. Its two reporting segments, according to its second-quarter release, are the United States, where revenue was about $1.3 billion in the quarter, and International, at about $1.2 billion. Companion animals, meaning dogs, cats and horses, are the larger and more profitable pool, with livestock covering cattle, poultry, swine and fish.

S&P Dow Jones Indices announced in a June 2013 release that Zoetis was set to join the S&P 500.

What the second quarter showed

For the three months ended June 30, 2026, Zoetis reported revenue of about $2.5 billion, flat on a reported basis and down 1% organically on an operational basis. Net income was $691 million, or $1.65 per diluted share, up 1%. Adjusted net income was $781 million, or $1.87 per share, up 5% as reported and 4% organically. These are historical, company-reported figures from the release of August 6, 2026.

The mix was uneven. In the United States, revenue fell 7%, with companion-animal products down 11%, which management attributed to lower clinic visits and pet-owner price sensitivity. US livestock rose 23%, helped by cattle and poultry. International revenue grew 8% reported and 6% organically, with parasiticides including Simparica Trio a driver of companion-animal growth abroad.

The company also flagged pressure on individual brands. Simparica Trio faced price sensitivity and competition, Cerenia and Convenia felt the effect of generic entrants, and sales of Librela, its osteoarthritis pain antibody for dogs, were lower. Chief executive Kristin Peck said the quarter reflected a more pressured companion-animal market.

Guidance reset

On August 6, 2026 Zoetis lowered its 2026 guidance. Revenue is now expected at $9.12 billion to $9.32 billion, compared with $9.68 billion to $9.96 billion given on May 7. Adjusted diluted earnings per share are guided at $6.15 to $6.25, down from $6.85 to $7.00. The revised range implies organic operational revenue declining by between 1% and 3%, against growth of 2% to 5% previously.

Growth drivers and industry backdrop

Management said it is responding with targeted investment, faster innovation and business development. Recent items in the release included the July 2026 acquisition of VitalRADS, a veterinary teleradiology platform that extends the company into diagnostics, and approvals for Lenivia and Portela, its long-acting osteoarthritis pain treatments, in Canada, the European Union, Great Britain and Switzerland. A US emergency use authorization for Dectomax products against New World screwworm and a poultry vaccine approval add to a livestock franchise that has been the quarter's brightest spot.

The wider industry question is whether softer veterinary visit volumes and stretched household budgets are cyclical or a longer adjustment. The company's own commentary points to demand, not supply, as the constraint. Generic competition in older products and rival launches in parasiticides and dermatology are structural factors that analysts will weigh against the pipeline.

Cash, debt, buybacks and the dividend

Zoetis authorized a multi-year $6 billion share repurchase program in August 2024 and priced $1.75 billion of convertible senior notes in 2025 in connection with buyback funding.

On dividends, the second-quarter 2026 declaration was $0.53 per share, with a record date of April 20, 2026 and payment on June 2, 2026. All figures cited are ordinary dividends, not special ones. The distinction between yields matters: trailing yield divides dividends actually paid over the past twelve months by price, while indicated yield annualizes the latest quarterly rate, here $2.12, so it is higher when payments have been rising.

Set against the midpoint of adjusted earnings guidance, $2.12 is around 34%, a simple calculation rather than a company target.

Risks

The principal risk is a prolonged softness in companion-animal demand, which the company itself identified. Others include pricing pressure, generic and branded competition, reliance on a handful of large franchises, regulatory and safety scrutiny of newer therapies, currency effects, and execution on acquisitions. Livestock strength may not persist, and further guidance revisions are possible.

Early November Results and the Next Dividend Declaration

Investors will look for the third-quarter results, normally reported in early November, and the fourth-quarter dividend declaration, for evidence on volumes, Librela and Simparica trends, and any change in capital allocation.